Kailera Therapeutics (KLRA) Stock Price, News & Analysis

Company Overview

Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets. Publicly available information about Kailera Therapeutics’ broader pipeline, geographic operations and leadership team is limited.

Key Stats

• Today's Range: $10.57 to $11.76
• 50-Day Range: $10.99 to $18.98
• 52-Week Range: $10.56 to $28.23
• Volume: 568,750 shs
• Average Volume: 810,575 shs
• Market Capitalization: $1.43 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.75
• Consensus Rating: Moderate Buy

Kailera Therapeutics Stock Analysis - MarketRank™

Kailera Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 529th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kailera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Kailera Therapeutics has a consensus price target of $42.75, representing about 302.2% upside from its current price of $10.63.

Amount of Analyst Coverage

Kailera Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kailera Therapeutics are expected to decrease in the coming year, from ($3.89) to ($4.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kailera Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kailera Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.60% of the float of Kailera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kailera Therapeutics has a short interest ratio ("days to cover") of 7.62.

Change versus previous month

Short interest in Kailera Therapeutics has recently increased by 5.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kailera Therapeutics does not currently pay a dividend.

Dividend Growth

Kailera Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.60

News Sentiment

Kailera Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Kailera Therapeutics this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for KLRA on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Kailera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kailera Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Kailera Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KLRA
• CIK: 2096997
• Web: www.kailera.com
• Phone: (508) 440-9475
• Fax: N/A
• Employees: 145
• Year Founded: 2024

Price Target and Rating

• Average Price Target for Kailera Therapeutics: $42.75
• High Price Target: $57.00
• Low Price Target: $30.00
• Potential Upside/Downside: +286.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.11
• Quick Ratio: 11.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 129,640,000
• Free Float: N/A
• Market Cap: $1.44 billion
• Optionable: N/A
• Beta: N/A